[
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "url": "https://finnhub.io/api/news?id=b93139f7396844d64e539a20b271afdc463f0bca32f5e463ef4fa89065002d94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765375802,
      "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
      "id": 137750212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
      "url": "https://finnhub.io/api/news?id=b93139f7396844d64e539a20b271afdc463f0bca32f5e463ef4fa89065002d94"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
    "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
    "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765362409,
      "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
      "id": 137747724,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307043297/image_1307043297.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
      "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Improving Balance Sheet Is Bringing The Stock Close To Being A \"Buy\"",
    "summary": "Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming patent expirations.",
    "url": "https://finnhub.io/api/news?id=4840ff46cf1e594fb26eb61f75ce958f1abab01371cc3e449149692463a249e0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765361253,
      "headline": "Amgen: Improving Balance Sheet Is Bringing The Stock Close To Being A \"Buy\"",
      "id": 137747641,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304930579/image_1304930579.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming patent expirations.",
      "url": "https://finnhub.io/api/news?id=4840ff46cf1e594fb26eb61f75ce958f1abab01371cc3e449149692463a249e0"
    }
  }
]